Oculis Holding AG
OCSHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Oculis Holding AG focuses on Biotechnology services and products. Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. At a $675.8M market cap, Oculis Holding AG ranks as a small-cap company within healthcare. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Market Cap
$675.8M
Beta
0.23
P/E (TTM)
—
P/E (Fwd)
-5.99
EPS (TTM)
$-1.70
EPS (Fwd)
$-2.03
ROE
-43.7%
ROA
-24.9%
Cash
$228.3M
Total Debt
$2.5M
Free CF
-$41.4M
52W Change
-29.2%
Annual Financials
Cash vs Debt
Where OCS stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, OCS finished 42.33% below its 150-day moving average ($21.12) and 42.41% below its 200-day moving average ($21.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OCS overbought or oversold?
At the September 2, 2026 close, OCS's RSI(14) was 35.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oculis Holding AG holds $228.3M in cash against $2.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$41.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Oculis Holding AG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OCS.